Whether COVID-19 booster is approved or not, Pfizer and Moderna have already made their money

Probably a few million Covid-1 boo booster shots will be rolled out in the U.S. next month, but that doesn’t mean companies like Moderna Inc. and Pfizer Inc. will report unexpected revenue cuts this year.

Both companies have already signed agreements with the U.S. government for additional levels in June and July, which have already turned into annual sens cuts by Wall Street analysts. (America is buying an additional 200 million doses each from Modern MRNA,
+ 1.54%
And Pfizer from PFE,
+ 0.07%,
Which has developed its vaccine with Biotech SE BNTX,

According to the Factset sens reduction, Pfizer is expected to sell ভ 9.6 billion in vaccine sales in the third quarter and .4 11.4 billion in the fourth quarter, with a total of .8 32.8 billion in Covid-1 vaccine sales in 2021.

Sales estimates for Modern Shot are much lower for the year. They are expected to reach 9 6.9 billion in the third quarter and 1 7.1 billion in the fourth quarter, bringing the total to .0 20.0 billion in 2021.

Sales figures include the initial series of shots and the booster dose.

Wall Street analysts have always known that the Covid-1 boo booster is on the table

The Wall Street view is that it is more than enough vaccines to qualify them in the United States and those who choose to take a third shot if it is approved.

The FDA approved a booster late Wednesday for people under 65 years of age or older, who have an underlying health condition and who are at high risk of covid infection at work.

“It will be proposed to boost all those who want it in part to avoid inequality in 1.1 [million] Those who have already got a booster (and more people are looking for a booster out there) and those who want to get one but can’t get one, “Jefferies analyst Michael E said Sept. 15.

While the Biden administration has put its full support behind a booster program for all adults in the United States and scientists are questioning the need to encourage people at the moment, Wall Street has become somewhat more realistic in its thinking.

Analysts have widely viewed the Covid-1 boo booster shots as a sure thing, warning that they would be limited to certain segments of the population, including the elderly and those who work on the frontline or have pre-existing conditions that put them at higher risk of illness.

This is the same lawsuit filed by members of the FDA committee last week and a CDC advisory committee a few weeks ago.

(In August the regulator approved a third dose of mRNA shots that were immunocompromised. Those shots were not seen as booster, however, because none of those individuals initially increased immunity.)

The FDA’s decision on the Biotech / Pfizer booster is imminent, and the regulatory process wheels are already spinning. On Friday, the FDA advisory committee recommended booster for the elderly and those at high risk of serious disease, and the CDC’s advisory committee on immunization practice is meeting Wednesday and Thursday to discuss who should receive the booster.

What about market share?

If there is some focus instead of investors, it is: the order in which booster shots are approved or approved.

The market share race is not very different from what happens with pharmaceuticals in our non-epidemic life. Since Pfizer is at the forefront, it is likely to become an influential supplier to the Covid-1 vaccine company in the United States, according to SVB Leerink analysts. The vaccine market is dominated by one or two players.

“Pfizer now looks set to dominate the first generation of Covid expansion, which will make it much harder for its existing competitors to gain a share and new competitors to enter the market,” they wrote in a note to investors on Saturday.

So far this year, Pfizer’s stock has risen 20.3%, while Modern’s shares have risen 320.8%. S&P 500 SPX,
+ 0.95%
Increased by 15.9% in 2021.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button